ADARx Pharmaceuticals (ADRX) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ADARx Pharmaceuticals is the larger company by market cap ($1.85 billion vs $1.85 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | SRPT |
|---|---|---|
| Share price | $17.33 | $17.50 |
| Market cap | $1.85B | $1.85B |
| 1-day change | -6.73% | +1.10% |
| YTD return | — | -18.68% |
| 1-year return | — | -24.31% |
| 5-year return | — | -79.21% |
| Forward P/E | — | 7.26 |
| EPS (TTM) | $-1.16 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.21 | $24.68 |
| 52-week low | $17.20 | $14.68 |
| Distance from 52-week high | -25.33% | -29.09% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | +24.17% |
| Average volume | 1.42M | 2.99M |
| Shares outstanding | 106.80M | 105.63M |
| Employees | 100 | 835 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: ADARx Pharmaceuticals in Healthcare and Sarepta Therapeutics in Health Care.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Healthcare · Biotechnology · 100 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
ADRX vs SRPT FAQ
Which is bigger, ADARx Pharmaceuticals or Sarepta Therapeutics?
ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.85B compared with $1.85B for Sarepta Therapeutics (SRPT).
Are ADARx Pharmaceuticals and Sarepta Therapeutics in the same industry?
No. ADARx Pharmaceuticals is in the Healthcare sector, while Sarepta Therapeutics is in Health Care.